Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | HRH1 | P35367 | 1/20 | 0.67 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | CPT2 | P23786 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232682 | 1.00 | MEN1 (0.73) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Hydrochloric Acid SCHEMBL9465317 | 0.98 | MEN1 (0.71) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL16238330 | 0.90 | MEN1 (0.73) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Levocarnitine Propionate SCHEMBL4557816 | 0.89 | MEN1 (0.76) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL6919852 | 0.89 | MEN1 (0.76) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL288495 | 0.88 | MEN1 (0.71) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL31011113 | 0.88 | MEN1 (0.71) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| SCHEMBL30513874 | 0.88 | MEN1 (0.71) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Valine SCHEMBL17164660 | 0.87 | MEN1 (0.57) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Alpha-Ketoglutaric Acid SCHEMBL4595160 | 0.87 | MEN1 (0.57) | MEN1KMT2ACYP2C19RECQLCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024264013-A1 | BIOAVAILABILITY ENHANCING IONIC LIQUID FORMULATIONS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-12-26 | — | — | WO | claimed |
| US-20230346735-A1 | Nutritional Composition Comprising Carnitine and Method for Treating or Preventing an Infection in a Mammal | LONZA GREENWOOD LLC | 2023-11-02 | — | — | US | claimed |
| EP-4125858-A1 | NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL | Lonza Consumer Health Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| CN-115684430-A | Application of nasopharyngeal carcinoma related serum marker in preparation of product for diagnosing/prognosing nasopharyngeal carcinoma | 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) | 2023-02-03 | — | — | CN | claimed |
| EP-4125858-B1 | NUTRITIONAL COMPOSITION COMPRISING L-CARNITINE TARTRATE FOR USE IN TREATING OR PREVENTING A CORONAVIRUS INFECTION IN A MAMMAL | LONZA GREENWOOD LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2024264013-A1 | BIOAVAILABILITY ENHANCING IONIC LIQUID FORMULATIONS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20230393041-A1 | Bead-Enabled, Efficient, and Rapid Multi-Omic Sample Preparation for Mass Spectrometry Analysis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-12-07 | — | — | US | disclosed |
| US-20230346735-A1 | Nutritional Composition Comprising Carnitine and Method for Treating or Preventing an Infection in a Mammal | LONZA GREENWOOD LLC | 2023-11-02 | — | — | US | disclosed |
| WO-2023145880-A1 | GLUTAMINASE INHIBITOR | 国立大学法人富山大学 | 2023-08-03 | — | — | WO | disclosed |
| EP-3154539-B1 | METHOD FOR DECREASING SKELETAL MUSCLE DAMAGE AND/OR OXIDATIVE STRESS IN MAMMALS | LONZA CONSUMER HEALTH INC (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-4125858-A1 | NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL | Lonza Consumer Health Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115684430-A | Application of nasopharyngeal carcinoma related serum marker in preparation of product for diagnosing/prognosing nasopharyngeal carcinoma | 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) | 2023-02-03 | — | — | CN | disclosed |
| US-20120148685-A1 | METHODS AND COMPOSITIONS FOR TREATING INSULIN RESISTANCE, DIABETES MELLITUS TYPE 2, METABOLIC SYNDROME AND RELATED DISORDERS | Engergy4Life AG (CH) | 2012-06-14 | — | — | US | disclosed |
| EP-2440201-A1 | METHODS AND COMPOSITIONS FOR TREATING INSULIN RESISTANCE, DIABETES MELLITUS TYPE 2, METABOLIC SYNDROME AND RELATED DISORDERS | Energy4life Ag (CH) | 2012-04-18 | — | — | EP | disclosed |
| EP-1962826-B1 | METHOD FOR WEIGHT REDUCTION | ENERGY4LIFE GMBH (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-20110261737-A1 | TRANSMIT AND RECEIVE METHOD FOR A DATA SERVICE | AT&T Intellectual Property II, L.P. (formerly known as AT&T CORP.) (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2010143053-A1 | METHODS AND COMPOSITIONS FOR TREATING INSULIN RESISTANCE, DIABETES MELLITUS TYPE 2, METABOLIC SYNDROME AND RELATED DISORDERS | ENERGY4LIFE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20090081320-A1 | Method for Weight Reduction | ENERGY4LIFE AG (CH) | 2009-03-26 | — | — | US | disclosed |
| EP-1962826-A2 | METHOD FOR WEIGHT REDUCTION | Energy4Life GmbH (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007066192-A2 | METHOD FOR WEIGHT REDUCTION | ENERGY4LIFE GMBH (CH) | 2007-06-14 | — | — | WO | disclosed |